<SEC-DOCUMENT>0001610520-26-000096.txt : 20260731
<SEC-HEADER>0001610520-26-000096.hdr.sgml : 20260731
<ACCEPTANCE-DATETIME>20260731164629
ACCESSION NUMBER:		0001610520-26-000096
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G/A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20260731
DATE AS OF CHANGE:		20260731

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			REVIVA PHARMACEUTICALS HOLDINGS, INC.
		CENTRAL INDEX KEY:			0001742927
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-90624
		FILM NUMBER:		261229230

	BUSINESS ADDRESS:	
		STREET 1:		10080 N WOLFE ROAD
		STREET 2:		SUITE SW3-200
		CITY:			CUPERTINO
		STATE:			CA
		ZIP:			95014
		BUSINESS PHONE:		4085018881

	MAIL ADDRESS:	
		STREET 1:		10080 N WOLFE ROAD
		STREET 2:		SUITE SW3-200
		CITY:			CUPERTINO
		STATE:			CA
		ZIP:			95014

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Tenzing Acquisition Corp.
		DATE OF NAME CHANGE:	20180606

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			UBS Group AG
		CENTRAL INDEX KEY:			0001610520
		STANDARD INDUSTRIAL CLASSIFICATION:	NATIONAL COMMERCIAL BANKS [6021]
		ORGANIZATION NAME:           	02 Finance
		EIN:				000000000
		STATE OF INCORPORATION:			V8
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A

	BUSINESS ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		BAHNHOFSTRASSE 45
		CITY:			ZURICH
		PROVINCE COUNTRY:   	V8
		ZIP:			CH-8001
		BUSINESS PHONE:		41-44-234-1111

	MAIL ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		BAHNHOFSTRASSE 45
		CITY:			ZURICH
		PROVINCE COUNTRY:   	V8
		ZIP:			CH-8001
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
  <schemaVersion>X0202</schemaVersion>
<headerData>
    <submissionType>SCHEDULE 13G/A</submissionType>
    <previousAccessionNumber>0001610520-26-000060</previousAccessionNumber>
    <filerInfo>
      <filer>
        <filerCredentials>
          <cik>0001610520</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <amendmentNo>1</amendmentNo>
      <securitiesClassTitle>Common Stock, par value $0.0001 per share</securitiesClassTitle>
      <eventDateRequiresFilingThisStatement>06/30/2026</eventDateRequiresFilingThisStatement>
      <issuerInfo>
        <issuerCik>0001742927</issuerCik>
        <issuerName>REVIVA PHARMACEUTICALS HOLDINGS, INC.</issuerName>
        <issuerCusips>
          <issuerCusipNumber>76152G209</issuerCusipNumber>
        </issuerCusips>
        <issuerPrincipalExecutiveOfficeAddress>
          <com:street1>10080 N WOLFE ROAD</com:street1>
          <com:street2>10080 N WOLFE ROAD</com:street2>
          <com:city>CUPERTINO</com:city>
          <com:stateOrCountry>CA</com:stateOrCountry>
          <com:zipCode>95014</com:zipCode>
        </issuerPrincipalExecutiveOfficeAddress>
      </issuerInfo>
      <designateRulesPursuantThisScheduleFiled>
        <designateRulePursuantThisScheduleFiled>Rule 13d-1(b)</designateRulePursuantThisScheduleFiled>
      </designateRulesPursuantThisScheduleFiled>
    </coverPageHeader>
    <coverPageHeaderReportingPersonDetails>

      <reportingPersonName>UBS Group AG</reportingPersonName>
      <citizenshipOrOrganization>V8</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>0.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>0.00</soleDispositivePower>
        <sharedDispositivePower>0.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>0.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <classPercent>0.0</classPercent>
      <typeOfReportingPerson>BK</typeOfReportingPerson>
    </coverPageHeaderReportingPersonDetails>
    <items>
      <item1>
        <issuerName>REVIVA PHARMACEUTICALS HOLDINGS, INC.</issuerName>
        <issuerPrincipalExecutiveOfficeAddress>10080 N WOLFE ROAD, 10080 N WOLFE ROAD, CUPERTINO, CALIFORNIA, 95014.</issuerPrincipalExecutiveOfficeAddress>
      </item1>
      <item2>
        <filingPersonName>UBS Group AG
</filingPersonName>
        <principalBusinessOfficeOrResidenceAddress>Bahnhofstrasse 45 PO Box CH-8021, Zurich, Switzerland
</principalBusinessOfficeOrResidenceAddress>
        <citizenship>Switzerland</citizenship>
      </item2>
      <item3>
        <notApplicableFlag>N</notApplicableFlag>
        <typeOfPersonFiling>BK</typeOfPersonFiling>
      </item3>
      <item4>
        <amountBeneficiallyOwned>0</amountBeneficiallyOwned>
        <classPercent>0</classPercent>
        <numberOfSharesPersonHas>
          <solePowerOrDirectToVote>0</solePowerOrDirectToVote>
          <sharedPowerOrDirectToVote>0</sharedPowerOrDirectToVote>
          <solePowerOrDirectToDispose>0</solePowerOrDirectToDispose>
          <sharedPowerOrDirectToDispose>0</sharedPowerOrDirectToDispose>
        </numberOfSharesPersonHas>
      </item4>
      <item5>
        <classOwnership5PercentOrLess>Y</classOwnership5PercentOrLess>
      </item5>
      <item6>
        <notApplicableFlag>Y</notApplicableFlag>
      </item6>
      <item7>
        <notApplicableFlag>N</notApplicableFlag>
        <subsidiaryIdentificationAndClassification>This statement on Schedule 13G is being filed by UBS Group AG on behalf of itself and its wholly owned subsidiaries UBS Financial Services Inc. and UBS Securities LLC.
</subsidiaryIdentificationAndClassification>
      </item7>
      <item8>
        <notApplicableFlag>Y</notApplicableFlag>
      </item8>
      <item9>
        <notApplicableFlag>Y</notApplicableFlag>
      </item9>
      <item10>
        <notApplicableFlag>N</notApplicableFlag>
        <certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under &amp;#167; 240.14a-11.

</certifications>
      </item10>
    </items>
    <signatureInformation>
      <reportingPersonName>UBS Group AG</reportingPersonName>
      <signatureDetails>
        <signature>Andrew Johnson </signature>
        <title>Director </title>
        <date>07/31/2026</date>
      </signatureDetails>
      <signatureDetails>
        <signature>Anjali Tiwari </signature>
        <title>Associate Director</title>
        <date>07/31/2026</date>
      </signatureDetails>
    </signatureInformation>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
